Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Arix Bioscience Plc LSE:ARIX London Ordinary Share GB00BD045071 ORD 0.001P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00 -0.52% 192.00 458,609 16:35:12
Bid Price Offer Price High Price Low Price Open Price
188.00 194.00 193.50 191.00 192.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.51 -75.57 -53.80 260
Last Trade Time Trade Type Trade Size Trade Price Currency
18:55:23 O 82,938 190.897 GBX

Arix Bioscience (ARIX) Latest News

More Arix Bioscience News
Arix Bioscience Investors    Arix Bioscience Takeover Rumours

Arix Bioscience (ARIX) Discussions and Chat

Arix Bioscience Forums and Chat

Date Time Title Posts
21/2/202101:50Arix Bioscience plc211
30/7/201810:14Arix Bioscience (ARIX) One to Watch -

Add a New Thread

Arix Bioscience (ARIX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
18:55:56190.9082,938158,326.15O
18:55:56190.9082,938158,326.15O
18:55:56190.9013,00024,816.61O
18:55:56190.9013,00024,816.61O
17:15:00190.00100,000190,000.00O
View all Arix Bioscience trades in real-time

Arix Bioscience (ARIX) Top Chat Posts

DateSubject
02/3/2021
08:20
Arix Bioscience Daily Update: Arix Bioscience Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ARIX. The last closing price for Arix Bioscience was 193p.
Arix Bioscience Plc has a 4 week average price of 166.50p and a 12 week average price of 164.50p.
The 1 year high share price is 229p while the 1 year low share price is currently 58.50p.
There are currently 135,609,653 shares in issue and the average daily traded volume is 285,877 shares. The market capitalisation of Arix Bioscience Plc is £260,370,533.76.
12/2/2021
12:27
pinemartin9: LONDON, 11 February 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, will announce its annual results for the year ended 31 December 2020, on Tuesday 9th March 2021. Arix will host a virtual analyst presentation on the same day, at 12:00pm GMT, followed by a Q&A session, accessible via conference call or webcast. The webcast of the presentation will be available on the Company's investor relations website at hxxps://arixbioscience.com/investor-relations/events-presentations.
09/2/2021
14:45
snappler: I hold Arix as well and looking for research about the other Neil Woodford backed biotech Investment Company, Malin Corp. The share price is EUR 6. i calculated the fair value around EUR 9, taking the recent share price performance of Immunocore and the sale of kymab into account. Do you know any interesting sites about malin?
26/1/2021
16:14
ohisay: But estimated cash here around 128p per share ..And Hardmans current Nav estimate is 274p a share . So market is effectively discounting the funds holdings by an enormous amount . viz .175p current share price less cash of 128p is 47p market valuation for remaining assets. Portfolio apparent Nav is 274p less 128p cash.....146p . Discount of 68%..
11/12/2020
11:31
eaaxs06: It's been a cracking week for Arix, with positive news flows from Atox Bio, Harpoon and Autolus, all within the past 4 days. On the back of the Harpoon news Peel Hunt has a target share price of 267p. which could be a very conservative guesstimate. Despite the share price coming a long way from the mid 50p days of early April, the market still haven't fully accepted its potential and look a great prospect for further improvement. Good luck everybody, Sid.
04/12/2020
16:10
rambutan2: Jane, looks more like IPO are being super conservative, or just forgot to update! As also an IPO holder I sometimes struggle to get my head round its valuation policy. ARIX, I would trust and say they'd be inline with the other VC investors. Was £15.3m at last investment round, a valuation which all participants should agree on as fixed as at that round: hTtps://arixbioscience.com/news/artios-completes-65m-series-b-investment-round Shows they upped valuations by £3.9m in first half of this year ie as progress shown, which Merck deal would seem to agree with: htTps://ether-assets.ams3.digitaloceanspaces.com/arix/Arix-interim-results-presentation-website-PDF.pdf?mtime=20200920115824&focal=none "IP Group has an 11.7% undiluted beneficial holding in Artios that was valued at £11.0m as at 30 June 2020. The directors anticipate that the Group's assessment of the value of its holding in Artios may increase by £5m-£15m as a result of the collaboration and will finalise this during the Group's 2020 Annual Results valuation process."
03/12/2020
19:09
ohisay: https://www.proactiveinvestors.co.uk/companies/news/935631/arix-bioscience-portfolio-company-artios-signs-cancer-collaboration-deal-with-merck-kgaa-worth-up-to-7bn-935631.html In a statement, Jonathan Tobin, managing director at Arix and an Artios board director, said: "Artios is a global powerhouse in DDR. Together with Merck KGaA's significant expertise and R&D resources, the collaboration will identify and develop precision oncology medicines targeting nucleases. “As early investors and the largest shareholder in Artios, we are proud of the company's success. It is a testament to its leadership team and strategy in developing a unique discovery platform of novel DNA repair nuclease inhibitors and targets, which will bring real impact to cancer patients." This collaboration follows the $2.75bn acquisition of Arix portfolio company VelosBio, last month, and reconfirms the potential of Arix’s private companies, it said. Jefferies analyst Ken Rumph commented: “With Arix still trading on a significant discount despite the Velos deal's boost to NAV and cash, more validation from another early-stage asset should attract more interest and narrow the discount.”
03/12/2020
08:09
n0rbie: Great piece of research from last month that I missed: Arix Bioscience (ARIX) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage biotech investing. ARIX minimises risk through a combination of an expert investment team and portfolio diversification. Along with its 2020 interim results, management provided the market with some aspirational targets for the next three years, which would see the NAV double to ca.£500m. News that Merck & Co is to acquire portfolio company, VelosBio, for $2.75bn cash, giving ARIX >12x return on its investment, will help to smash these targets. Strategy: ARIX sources investments from an established network and a strong scientific reputation. The portfolio is diversified by therapeutic area, treatment modality, stage of discovery/development and geography to balance the risk-reward profile. Value is realised when ARIX successfully exits its investments. Acquisition of VelosBio: Major pharmaceutical company, Merck & Co (MRK), has announced the acquisition VelosBio for $2.75bn cash, to boost its position in oncology and provide it with another breakthrough technology in this field. The transaction, subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act, is expected to close by the end of 2020. Return on investment: VelosBio was introduced to ARIX by its strategic partner, Takeda Ventures. ARIX co-led the company’s Series A funding round in 2018, committing $11m/£8.6m, and made a further investment of $4.0m/£3.2m in VelosVio’s Series B in July 2020. ARIX is expecting to receive $185m/£142m for its stake, representing a 12.3x return. Market reaction: Although the market responded favourably to this news, with the shares rising 55%, this equates to an increase in market capitalisation of only £74m compared with the £121m valuation uplift from the VelosBio consideration, and has expanded the discount to NAV from 31% to 34%. This suggests that the shares have much further to go. Investment summary: The principal reason that ARIX has been trading on a discount to its NAV has been the “lack of a track record”. Management tried to allay the market’s concern with its interim results when it highlighted the portfolio’s IRR of 20% since inception and set itself some ambitious targets for the next three years. The trade sale of VelosBio means that these targets should be easily met and the market should be giving far more credit to the company. https://www.hardmanandco.com/research/corporate-research/hitting-the-jackpot/
05/11/2020
12:21
eaaxs06: All interesting stuff, with Arix's share being worth £121m increase, equiv to 89p a share, there should be more to come with the share price at around 160p.
08/9/2020
09:04
ohisay: https://www.londonstockexchange.com/news-article/ARIX/arix-bioscience-plc-interim-results-for-the-six-months-ended-30-june-2020/14678115 https://arixbioscience.com/investor-relations/events-presentations Presentations ...and webcast at 1230 if anybody's interested . Nav of 185p suggests overlarge disconnect with the share price especially with 32p per share cash on the balance sheet..I've added this morning .
20/2/2020
07:52
stevenb3: Iterium and LogicBio were both up 11% yesterday on NASDAQ. However, I don't expect this to follow through into the Arix share price.
Arix Bioscience share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
ARIX
Arix Biosc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210302 21:10:36